Martin Abeloff, head of oncology and director of the Johns Hopkins Kimmel Cancer Center since 1992, an international authority on breast cancer, died of leukemia yesterday. The John Hopkins Center says Abeloff will be remembered by his friends and colleagues worldwide for his distinctive humility, humor and astonishing dedication to his patients and students. [click link for full article]
More: continued here
Iodine has been used as an antimicrobial for the last century. Much has been written about molecular iodine yet many women suffering from Fibrocystic Breast Disease (FBD) are unaware that studies being conducted may soon yield an effective nonhormonal treatment. While there are several breast cancer drugs on the market, all available hormonal therapies have significant adverse events. [click link for full article]
More: continued here
Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Susan Greenspan, M.D. [click link for full article]
More: continued here
The number of breast cancer cases among women in Hong Kong increased from 1,152 in 1993 to 2,273 in 2004, the Hong Kong Breast Cancer Foundation announced Thursday, China Daily/China.org.cn reports. According to the World Health Organization, Hong Kong has a breast cancer incidence of 47. [click link for full article]
More: continued here
Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug paclitaxel onto tiny gold spheres. The result is a tiny ball, many times smaller than a living cell that literally bristles with the drug.Paclitaxel, which is sold under the brand name Taxol
Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour’s response to chemotherapy and, therefore, the patient’s ultimate likelihood of survival. [click link for full article]
More: continued here
Evista (raloxifene HCl), a drug aimed at reducing invasive breast cancer risk for both postmenopausal women with osteoporosis and postmenopausal women with a invasive breast cancer risk has been approved by the US Food and Drug Administration (FDA) for both groups of women. Gwen Krivi, Ph.D., VP, Lilly Research Laboratories “The FDA’s decision marks a major milestone. [click link for full article]
More: continued here
A way of predicting which patients will respond well to treatment with a common chemotherapy drug used in breast cancer was unveiled at the European Cancer Conference (ECCO 14). Dr Iain Brown, from the University of Aberdeen, Aberdeen, Scotland, told the conference that he and his colleague, Dr Andrew Schofield, had identified two genes that could identify which cells would be resistant and which would respond to docetaxel. [click link for full article]
More: continued here
The breast cancer mortality rate in the U.S. decreased by about 2% annually from 2001 to 2004, according to an American Cancer Society report released Tuesday, Reuters reports. The report — titled “Breast Cancer Facts & Figures, 2007-2008″ — found breast cancer diagnoses decreased by 3. [click link for full article]
More: continued here
A new report by the American Cancer Society (ACS) shows that in the US, the overall rate of deaths from breast cancer in women continues to fall by around 2 per cent a year, a trend that started in 1990. However stark racial disparities within this figure continue to grow.The ACS produce the report, in this case titled Breast Cancer Facts and Figures 2007-2008, every other year. [click link for full article]
More: continued here





